Spyre Therapeutics

Spyre Therapeutics

Biotechnology
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

$9.3B

Market Cap • 10/20/2026

2013

(13 years)

Founded

2016

(10 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

8,5

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

10,8

EPS

—

Market Cap

Market Cap

9,3B

EV

8,3B

EV/Revenue

0

EV/EBITDA

-41,3

EV/EBIT

-41,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-8,4%

Total Yield

-8,4%

Payout

0%

Retained Earnings

-1,2B

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

25,1%

CAGR Net Income 5Y

22,1%

CAGR EPS 5Y

-40%

CAGR OCF 5Y

32%

Leverage

N.D./EBITDA

5,7

Debt/Equity

0%

Current Ratio

18,5

Quick Ratio

18,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium